

## Genetics and Genomics Seminar Series



**Bolin Liu, MD**

Professor

Department of Interdisciplinary Oncology  
LSU Health New Orleans

### **“Resistance to Targeted Therapy in HER2-positive Breast Cancer”**

Friday, March 31, 2023

12:00pm

Register in advance for this meeting:

[https://uab.zoom.us/meeting/register/tZMscequrzkuHtYqj2SIS2Z1\\_cPHERyzTRK9](https://uab.zoom.us/meeting/register/tZMscequrzkuHtYqj2SIS2Z1_cPHERyzTRK9)

Target Audience: UAB Broader Genetics Community

#### Disclosures and acknowledgements:

- Bolin Liu, MD has no actual or potential conflict of interest in relation to this program/presentation.
- The following planners, speakers, moderators, and/or panelists of this CE activity have no relevant financial relationships with commercial interests to disclose: Lizhong Wang, PhD; Runhua Liu, PhD.

There is no commercial support for this session

Objectives: After attending this session, participants will gain insights into the following:

1. Receptor tyrosine kinases in HER2-positive breast cancer progression
2. Both HER3- and IGF-1R-initiated signaling pathways play an important role in the development of resistance to HER2-targeted therapy.
3. Dysregulation of the PPP3CB/FOXO3a/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
4. RNA m6A modification via ALKBH5-mediated demethylation represents a novel mechanism of resistance to HER2-targeted therapy.

Sponsored for CME Credit by UAB Division of CME

The University Of Alabama School Of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University Of Alabama School Of Medicine designates this Regularly Scheduled Series session for a maximum of 1 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The University Of Alabama School Of Medicine is an equal opportunity/affirmative action institution.